Preamble:
It is mandatory for every medical college in India to have a Pharma covigilance Committee, as per regulations of National Medical Council, 2020. Therefore, the Pharma covigilance Committee of Swamy Vivekanandha Medical College and Research institute is constituted as follows:-
| S.N0 | Name | Designation | Designation in the committee |
| 1 | Dr. S. Balasubramanian | Dean | Chairperson |
| 2 | Dr.M.Manoharan | Medical Superintendent | Member Secretary |
| 3 | Dr.J.Mohan | Professor of Pharmacology | Convener |
| 4 | Dr.K.Krupanidhi | Deputy Medical Superintendent | Member |
| 5 | Dr.J.Priya | Assistant Professor of General Medicine | Member |
| 6 | Dr. M.Rajendran | Professor of General Surgery | Member |
| 7 | Dr.K.Vimala | Assistant Professor of Obstetrics & Gynecology | Member |
| 8 | Dr.S.Rajeswaran | Professor of Anesthesiology | Member |
| 9 | Mrs.N.Latha | Nursing Superintendent Grade II | Member |
| 10 | Mrs.Sasikala | Pharmacist | Member |
Goal:
The goal of the committee in general will be to generate awareness about the need of the identifying and reporting of Adverse Drug Reactions(ADRs) amongst all sections of health care providers( Doctors, Nurses, Pharmacist, Post-graduates and Under-graduate students, Service providers, etc) of SVMCH & RI to identify ADR occurring in patients visiting the hospital and report the same to the appropriate authorities.
Scope of the committee:
The committee shall meet once in 2 months and be responsible for planning, implementation and monitoring of various activities of the Pharma covigilance programme of India (PvPI). The committee will also function as mentors and facilitators.
Objectives:
- To generate awareness about ADR’s amongst health care providers and students of the institute, through various activities.
- To identify ADR’s occurring in the patients visiting the hospital for treatment and to report the same to the appropriate authorities.
- To carry out causality assessment of ADR’s
- To understand scientific and research activities pertaining to ADR’s
- To initiate activities to strengthen the ongoing Pharma covigilance programme
